Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509795 · ClinicalTrials.gov registry record · Phase 3
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
A Phase 3 study of Macular Degeneration, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,217
- Enrollment target
- 20
- Study locations
NCT00509795 is a Phase 3 study of Macular Degeneration that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,217 participants, above the 132-participant average among 26 other Macular Degeneration trials with a reported enrollment target (822% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT00509795, a Phase 3 study of Macular Degeneration, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,217 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.
Conditions Studied
Interventions
- BIOLOGICAL ranibizumab
- BIOLOGICAL aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Study Locations (20)
California
- - Beverly Hills
- - Campbell
- - Fullerton
- - Glendale
- - Irvine
- - La Jolla
- - Loma Linda
- - Los Angeles
- - Los Angeles
- - Menlo Park
- - Mountain View
- - Oakland
- - Palm Springs
- - Pasadena
Arizona
- - Phoenix
- - Phoenix
- - Tucson
- - Tucson
Alabama
- - Birmingham
- - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,217 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509795
The ClinicalTrials.gov registry entry for NCT00509795 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,217 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 132-participant average among 26 other Macular Degeneration trials with a reported enrollment target (822% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which ranibizumab is the first listed.
NCT00509795 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00509795 about?
NCT00509795 is a clinical study titled "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)". This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.
What is the current status of trial NCT00509795?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,217 participants. The study started on 2007-08. Estimated completion is 2011-07.
What conditions does trial NCT00509795 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT00509795?
The interventions under investigation include: ranibizumab (BIOLOGICAL), aflibercept injection (VEGF Trap-Eye, BAY86-5321) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00509795?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00509795 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
COMPLETED · Phase 3
-
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
COMPLETED · Phase 3
-
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 3
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.